Darolutamide plus ADT and radiation therapy reduces risk of metastasis or death by 58% in prostate cancer patients at high risk of recurrence
ORION CORPORATION PRESS RELEASE 24 OCTOBER 2026 at 9.35 EEST
Covered in this story
Call it yourself
No calls on $ADT yet. A scorecard is a price target with a date and the working behind it — tracked, settled and scored in public.
Make the first call on ADT →Summary aggregated from GlobeNewswire's public RSS feed. The full reporting belongs to GlobeNewswire — please read it on their site.